Literature DB >> 2249048

Rising mortality from cryptogenic fibrosing alveolitis.

I Johnston1, J Britton, W Kinnear, R Logan.   

Abstract

OBJECTIVE: To determine the pattern of mortality ascribed to cryptogenic fibrosing alveolitis and to identify factors that might be important in the aetiology of the disease; and to assess the validity of death certification of the disease.
DESIGN: A retrospective examination of mortality ascribed to cryptogenic fibrosing alveolitis in England and Wales between 1979 and 1988 with analysis, by multiple logistic regression, of independent effects of age, sex, region of residence, and social class as indicated by occupation on data for 1979-87; also a retrospective review of hospital records of patients certified as having died of cryptogenic fibrosing alveolitis in Nottingham and of the certified cause of death of patients known to have had the disease. MAIN OUTCOME MEASURES: Time trends in mortality nationally; effects on mortality of age, sex, and region of residence; validity of death certification in Nottingham.
RESULTS: The annual number of deaths ascribed to cryptogenic fibrosing alveolitis doubled from 336 in 1979 to 702 in 1988, the increase occurring mainly at ages over 65. Mortality standardised for age for both sexes likewise increased steadily over the period. Deaths due to cryptogenic fibrosing alveolitis were commoner in men (odds ratio 2.24, 95% confidence interval 2.11 to 2.33) and increased substantially with age, being 7.84 (7.24 to 8.49) times higher in subjects aged much greater than 75 than those aged 45-64. Odds ratios of death due to cryptogenic fibrosing alveolitis adjusted for age and sex were increased in the traditionally industrialised central areas of England and Wales (p less than 0.02, maximum odds ratio between regions 1.25), but no significant increase in odds of death was found for manual occupations. Of 23 people whose deaths were registered in Nottingham as having been due to cryptogenic fibrosing alveolitis, 19 were ascertained from clinical records to have had the disease. Only 17 of 45 patients known to have had cryptogenic fibrosing alveolitis in life were recorded as having died from the disease.
CONCLUSIONS: The diagnostic accuracy of death certification of cryptogenic fibrosing alveolitis is high, but the number of deaths recorded as being due to the disease may underestimate the number of patients dying with the disease by up to half. Mortality due to the disease is increasing, and the male predominance and regional differences in mortality suggest that environmental factors are important in its aetiology.

Entities:  

Mesh:

Year:  1990        PMID: 2249048      PMCID: PMC1664054          DOI: 10.1136/bmj.301.6759.1017

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  10 in total

1.  Idiopathic pulmonary fibrosis: cellular and molecular pathogenesis.

Authors:  J C Weissler
Journal:  Am J Med Sci       Date:  1989-02       Impact factor: 2.378

2.  The prognosis of cryptogenic fibrosing alveolitis.

Authors:  B H Stack; Y F Choo-Kang; B E Heard
Journal:  Thorax       Date:  1972-09       Impact factor: 9.139

Review 3.  Interstitial lung diseases of unknown cause. Disorders characterized by chronic inflammation of the lower respiratory tract (first of two parts).

Authors:  R G Crystal; P B Bitterman; S I Rennard; A J Hance; B A Keogh
Journal:  N Engl J Med       Date:  1984-01-19       Impact factor: 91.245

4.  Prognosis of cryptogenic fibrosing alveolitis.

Authors:  P Tukiainen; E Taskinen; P Holsti; O Korhola; M Valle
Journal:  Thorax       Date:  1983-05       Impact factor: 9.139

5.  Distribution of HLA antigens in idiopathic pulmonary fibrosis.

Authors:  J D Fulmer; M S Sposovska; E R von Gal; R G Crystal; K K Mittal
Journal:  Am Rev Respir Dis       Date:  1978-07

6.  Natural history and treated course of usual and desquamative interstitial pneumonia.

Authors:  C B Carrington; E A Gaensler; R E Coutu; M X FitzGerald; R G Gupta
Journal:  N Engl J Med       Date:  1978-04-13       Impact factor: 91.245

7.  HLA in cryptogenic fibrosing alveolitis.

Authors:  C W Turton; L M Morris; S D Lawler; M Turner-Warwick
Journal:  Lancet       Date:  1978-03-04       Impact factor: 79.321

8.  Is there a fibrotic gene?

Authors:  P B Bitterman; R G Crystal
Journal:  Chest       Date:  1980-10       Impact factor: 9.410

9.  [Epidemiological studies on idiopathic diffuse interstitial fibrosis of the lung (author's transl)].

Authors:  K Iwai; T Nakajima; Y Miyagi; S Ota; M Rokusha; S Okada; Y Moritani; Y Yamamoto; T Nobechi
Journal:  Nihon Kyobu Shikkan Gakkai Zasshi       Date:  1980-11

10.  Cryptogenic fibrosing alveolitis: response to corticosteroid treatment and its effect on survival.

Authors:  M Turner-Warwick; B Burrows; A Johnson
Journal:  Thorax       Date:  1980-08       Impact factor: 9.139

  10 in total
  27 in total

Review 1.  Review of cryptogenic fibrosing alveolitis, including current treatment guidelines.

Authors:  S C Bourke; H Clague
Journal:  Postgrad Med J       Date:  2000-10       Impact factor: 2.401

Review 2.  The diagnosis, assessment and treatment of diffuse parenchymal lung disease in adults. Introduction.

Authors: 
Journal:  Thorax       Date:  1999-04       Impact factor: 9.139

3.  Does cryptogenic fibrosing alveolitis carry an increased risk of death from lung cancer?

Authors:  J M Harris; P Cullinan; J C McDonald
Journal:  J Epidemiol Community Health       Date:  1998-09       Impact factor: 3.710

4.  Adult familial cryptogenic fibrosing alveolitis in the United Kingdom.

Authors:  R P Marshall; A Puddicombe; W O Cookson; G J Laurent
Journal:  Thorax       Date:  2000-02       Impact factor: 9.139

5.  The burden of lung disease.

Authors:  R Hubbard
Journal:  Thorax       Date:  2006-07       Impact factor: 9.139

6.  Adult height and cryptogenic fibrosing alveolitis: a case-control study using the UK general practice research database.

Authors:  R Hubbard; A Venn
Journal:  Thorax       Date:  2000-10       Impact factor: 9.139

7.  Pulmonary fibrosis is associated with an elevated risk of thromboembolic disease.

Authors:  D B Sprunger; A L Olson; T J Huie; E R Fernandez-Perez; A Fischer; J J Solomon; K K Brown; J J Swigris
Journal:  Eur Respir J       Date:  2011-07-07       Impact factor: 16.671

8.  Specialist palliative care is more than drugs: a retrospective study of ILD patients.

Authors:  Sabrina Bajwah; Irene J Higginson; Joy R Ross; Athol U Wells; Surinder S Birring; Amit Patel; Julia Riley
Journal:  Lung       Date:  2012-01-05       Impact factor: 2.584

9.  Mortality rates from cryptogenic fibrosing alveolitis in seven countries.

Authors:  R Hubbard; I Johnston; D B Coultas; J Britton
Journal:  Thorax       Date:  1996-07       Impact factor: 9.139

10.  Accuracy of mortality data for interstitial lung diseases in New Mexico, USA.

Authors:  D B Coultas; M P Hughes
Journal:  Thorax       Date:  1996-07       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.